Top 10 Companies in the Global Pharmaceutical Soybean Oil Market (2026): Market Leaders Powering Global Pharma

MARKET INSIGHTS

Global pharmaceutical soybean oil market size was valued at USD 234.5 million in 2024. The market is projected to grow from USD 245.8 million in 2025 to USD 400.5 million by 2034, exhibiting a CAGR of 5.2% during the forecast period.

Pharmaceutical‑grade soybean oil is a highly refined vegetable oil derived from soybeans, processed to meet stringent pharmacopeial standards for purity and stability. It serves as a key excipient in drug formulations, primarily functioning as an emulsion stabiliser, solvent, or carrier for lipophilic active pharmaceutical ingredients (APIs). The oil is classified into injectable and oral grades, with the former requiring additional purification to meet parenteral administration requirements.

Market growth is driven by expanding applications in intravenous nutrition, softgel capsule production, and topical formulations, while regulatory approvals for plant‑based excipients create new opportunities. However, price volatility of raw soybeans presents a persistent challenge. Leading manufacturers are investing in sustainable sourcing and advanced refining technologies to enhance product consistency and meet evolving pharmacopoeia standards across regions.

Global Pharmaceutical Soybean Oil Market – View in Detailed Research Report

Top 10 Companies in the Global Pharmaceutical Soybean Oil Market (2026)

1️⃣ Guangzhou Hanfang Pharmaceutical Co., Ltd

Headquarters: Guangzhou, China
Key Offering: Pharmaceutical‑grade soybean oil for injectable and oral applications

Guangzhou Hanfang has established a vertically integrated chain that spans soybean cultivation, solvent‑free extraction, and cGMP‑certified refining. This approach has allowed the company to maintain consistent purity levels while scaling production to meet the growing demand from Asia‑Pacific contract manufacturers.

Sustainability & Growth Initiatives:

• Adoption of high‑oleic soybean varieties to improve oxidative stability in lipid emulsions.
• Investment in renewable energy for downstream processing to reduce carbon footprint.
• Partnerships with local farmers to secure non‑GMO, sustainably farmed soybeans.

2️⃣ ADM‑SIO (Archer Daniels Midland Specialty Ingredients Operations)

Headquarters: Chicago, United States
Key Offering: Pharmaceutical‑grade soybean oil with advanced purification modules

ADM‑SIO’s recent USD 45 million investment in a new cGMP‑certified facility in Iowa positions it as a key supplier for U.S. and European pharmaceutical developers seeking domestic sources that meet strict USP and EP standards.

Sustainability & Growth Initiatives:

• Implementation of a closed‑loop water recycling system in the refining plant.
• Expansion of high‑purity production lines to support injectable excipient markets.
• Collaboration with research institutions to develop next‑generation solvent‑free extraction technologies.

3️⃣ Zhejiang Tianyushan Medicinal Oil Co., Ltd

Headquarters: Zhejiang, China
Key Offering: Solvent‑free extracted soybean oil for pharmaceutical and nutraceutical use

By leveraging a proprietary extraction process that eliminates the need for chemical solvents, Tianyushan has achieved a 37% export growth in 2023, capturing a significant share of the European market where regulatory bodies favour non‑chemical processing.

Sustainability & Growth Initiatives:

• Certification of its supply chain under the Global Good Agricultural Practices (GGAP) framework.
• Deployment of solar‑powered extraction units in its main production facility.
• Strategic alliances with European contract manufacturers to co‑develop high‑purity grades.

4️⃣ Xinxing Pharma (Yaopharma)

Headquarters: Shanghai, China
Key Offering: Injectable soybean oil for parenteral nutrition and drug delivery systems

With a focus on high‑purity standards, Xinxing Pharma has secured contracts with several leading global pharmaceutical companies for the supply of injectable excipients used in critical care and neonatal nutrition.

Sustainability & Growth Initiatives:

• Investment in high‑oleic soybean cultivation to meet the needs of lipid‑emulsion‑based nutrition products.
• Implementation of ISO 14001 environmental management system across all production sites.
• Research into antioxidant‑enhanced formulations to extend shelf life.

5️⃣ Henry Lamotte Oils GmbH

Headquarters: Hamburg, Germany
Key Offering: Pharmaceutical‑grade soybean oil compliant with European Pharmacopoeia

Lamotte Oils has positioned itself as a premium supplier for European manufacturers seeking non‑GMO, sustainably sourced soybean oil that meets stringent sterol and oxidation requirements.

Sustainability & Growth Initiatives:

• Partnership with German farmers to source certified organic soybeans.
• Implementation of a zero‑waste policy in the refining process.
• Development of a high‑purity line for softgel capsule production.

6️⃣ Croda International Plc

Headquarters: London, United Kingdom
Key Offering: Advanced lipid excipients for drug delivery and nutraceutical applications

Croda’s portfolio includes a range of soybean‑derived oils that meet USP, EP, and USP‑NF standards, making it a preferred partner for manufacturers targeting both pharmaceutical and nutraceutical markets.

Sustainability & Growth Initiatives:

• Investment in high‑oleic soybean breeding programmes.
• Implementation of carbon‑neutral production processes.
• Collaboration with universities to develop novel cryoprotectant formulations.

7️⃣ Avanti Polar Lipids (Subsidiary of Croda)

Headquarters: Wilmington, United States
Key Offering: Specialty lipid excipients for biologics and vaccine formulations

Avanti Polar Lipids has built a strong reputation for delivering ultra‑pure soybean oil suitable for biologic stabilisation and vaccine adjuvant systems, supporting the rapid expansion of the biologics market.

Sustainability & Growth Initiatives:

• Development of antioxidant‑rich formulations to enhance biologic stability.
• Use of renewable energy sources in all manufacturing sites.
• Partnerships with vaccine manufacturers to co‑develop next‑generation adjuvants.

8️⃣ Lipoid GmbH

Headquarters: Hamburg, Germany
Key Offering: Pharmaceutical‑grade soybean oil for injectable and oral applications

Lipoid’s focus on strict cGMP compliance and high‑purity standards has made it a trusted supplier for manufacturers of injectable drug products and softgel capsules.

Sustainability & Growth Initiatives:

• Implementation of a closed‑loop water recycling system.
• Adoption of high‑oleic soybean varieties to reduce oxidation risk.
• Research into biodegradable packaging solutions for finished products.

9️⃣ Cargill Pharmaceuticals

Headquarters: Chicago, United States
Key Offering: Large‑scale production of pharmaceutical‑grade soybean oil for global markets

Cargill’s extensive agricultural network and refining capacity allow it to supply consistent, high‑purity soybean oil to manufacturers across North America, Europe, and Asia‑Pacific.

Sustainability & Growth Initiatives:

• Investment in high‑oleic soybean breeding to improve product stability.
• Implementation of renewable energy in refining operations.
• Collaboration with contract manufacturers to expand product portfolios.

🔟 Global Pharmaceutical Soybean Oil Market – View in Detailed Research Report

Global Pharmaceutical Soybean Oil Market – View in Detailed Research Report

Download FREE Sample Report

Download FREE Sample Report: Click here to access the sample

Get Full Report

Get Full Report: Click here to purchase the full market analysis

Outlook

The next decade will see a continued shift towards natural excipients as pharmaceutical developers seek to meet regulatory demands for biocompatibility and patient safety. In parallel, the rise of biologic therapies and advanced drug delivery platforms will increase the demand for high‑purity soybean oil as a stabiliser and carrier. Manufacturers that invest in high‑oleic variants and advanced refining technologies will be well‑positioned to capture this momentum.

Future Trends

Key emerging trends include:

• Expansion of high‑purity, high‑oleic soybean oil lines to support injectable lipid emulsions and biologic stabilisers.
• Growth of veterinary pharmaceutical applications, driven by increased demand for injectable lipid formulations in livestock and companion animals.
• Adoption of soybean oil in nutraceuticals, particularly as a carrier for fat‑soluble vitamins and Omega‑3 supplements.
• Continued focus on sustainability, with suppliers prioritising non‑GMO, renewable‑energy‑powered production and closed‑loop water systems.
• Integration of advanced antioxidant systems to extend shelf life and improve product stability across dosage forms.